<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206739</url>
  </required_header>
  <id_info>
    <org_study_id>01KA0202-K7.3</org_study_id>
    <secondary_id>01KA0202</secondary_id>
    <nct_id>NCT00206739</nct_id>
  </id_info>
  <brief_title>Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants</brief_title>
  <official_title>Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernhard Nocht Institute for Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutscher Akademischer Austausch Dienst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Volkswagen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bernhard Nocht Institute for Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of Intermittent Preventive Treatment
      in Infants (IPTi) with Sulfadoxine-Pyrimethamine to reduce the numbers of malaria attacks,
      episodes of anemia, and the overall morbidity and mortality
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to define the effectiveness of Intermittent Preventive Treatment in Infants (IPTi)
      with Sulfadoxine-Pyrimethamine, a novel principle of malaria intervention, the following
      parameters are evaluated: i) the level of protection from malaria attacks and episodes of
      anemia during the treatment period, ii) the level of protection from severe malaria during
      the treatment period, iii) the effect on malaria morbidity after sustaining treatment, iv)
      the decrease of overall morbidity and mortality, including the number of hospital admissions
      and visits of hospital outpatient departments v) the influence of the intervention on the
      development of drug resistances, vi) the impact of the intervention on the development of
      immunity, vii) the possible influence of the intervention on sub-clinical organ dysfunction
      due to chronic Plasmodium falciparum infection. Parts of the study are performed in
      collaboration with the Laboratory of Research, Hospital Albert Schweitzer, Lambaréné, Gabon
      and the School of Medicine and Health Sciences, University of Development Studies, Tamale,
      Ghana
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Efficacy of an extended intermittent treatment with sulfadoxine-pyrimethamine for the control of clinical malaria and anemia (proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 21 months of life)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>• Determination of the rate of clinical malaria and anemia after suspending an extended intermittent treatment for analysis of possible rebound effects</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>• Evaluation of safety and adverse effects of the administration of single doses of sulfadoxine-pyrimethamine in infants and children</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Rate and time points of hospitalizations with anemia, malaria or other diseases</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Rate and time points of severe anemia episodes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 12 months of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Antibody responses against parasite antigens</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Multiplicity of P. falciparum infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Proportion of P. falciparum isolates with SP resistance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Influence of host genetic variants on the rate of P. falciparum infections</measure>
  </secondary_outcome>
  <enrollment type="Actual">1070</enrollment>
  <condition>Malaria</condition>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent by parent/guardian (written or oral)

          -  Permanent residentship in the study area

          -  Age of 3 months +/-4 weeks

        Exclusion Criteria:

          -  Hypersensitivity to sulfonamides or pyrimethamine (skin rashes, evidence of hemolysis
             including dark urine and/or purpura, presumptive signs of bone marrow depression such
             as sore throat and/or mouth ulcers)

          -  Other severe adverse events related to pyrimethamine-sulfadoxine application

          -  Signs of severe hepatic or renal dysfunction not due to malaria

          -  Other reasons after decision of the study physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ohene Adjei, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kumasi Centre for Collaborative Research in Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jürgen May, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Bernhard Nocht Institute for Tropical Medicine Hamburg, Infection Epidemiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kumasi Centre for Collaborative Research in Tropical Medicine</name>
      <address>
        <city>Kumasi</city>
        <state>Ashanti Region</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ghana</country>
  </location_countries>
  <link>
    <url>http://www15.bni-hamburg.de/bni/bni2/neu2/getfile.acgi?area_engl=researchgroups&amp;pid=2133</url>
    <description>Homepage of the Research Group Infection Epidemiology (co-ordination)</description>
  </link>
  <reference>
    <citation>Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001 May 12;357(9267):1471-7.</citation>
    <PMID>11377597</PMID>
  </reference>
  <reference>
    <citation>Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, Acosta CJ, Schellenberg DM, Galindo CM, Kimario J, Urassa H, Brabin B, Smith TA, Kitua AY, Tanner M, Alonso PL. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet. 1997 Sep 20;350(9081):844-50.</citation>
    <PMID>9310602</PMID>
  </reference>
  <reference>
    <citation>Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Rønn AM, Theander TG, Bygbjerg IC. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet. 2003 May 31;361(9372):1853-60.</citation>
    <PMID>12788572</PMID>
  </reference>
  <reference>
    <citation>Verhoef H, West CE, Nzyuko SM, de Vogel S, van der Valk R, Wanga MA, Kuijsten A, Veenemans J, Kok FJ. Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. Lancet. 2002 Sep 21;360(9337):908-14. Erratum in: Lancet 2002 Oct 19;360(9341):1256.</citation>
    <PMID>12354473</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 29, 2010</last_update_submitted>
  <last_update_submitted_qc>March 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2010</last_update_posted>
  <keyword>Malaria</keyword>
  <keyword>Anemia</keyword>
  <keyword>IPTi</keyword>
  <keyword>Intermittent Preventive Treatment in Infants</keyword>
  <keyword>Sulfadoxine-Pyrimethamine</keyword>
  <keyword>Chemoprophylaxis</keyword>
  <keyword>Ghana</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

